Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 177.78% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 38.89% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 372.22% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 66.67% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 316.67% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 177.78% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 205.56% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 150% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 344.44% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 427.78% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 177.78% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 233.33% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 455.56% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 872.22% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 816.67% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1566.67% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1622.22% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1566.67% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1205.56% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 955.56% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1011.11% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 927.78% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/04/2023 | 177.78% | 摩根士丹利 | $10→$10 | 重申 | 等重→等重 |
| 08/04/2023 | 38.89% | 巴克莱 | $7→$5 | 维护 | 等重 |
| 03/17/2023 | 372.22% | HC Wainwright公司 | $15→$17 | 维护 | 买 |
| 2022年11月21日 | 66.67% | B of A证券 | →$6 | 评级下调 | 中性→表现不佳 |
| 2022年11月17日 | 316.67% | HC Wainwright公司 | $16→$15 | 维护 | 买 |
| 2022年11月15日 | 177.78% | 摩根士丹利 | $11→$10 | 维护 | 等重 |
| 09/09/2022 | 205.56% | 摩根士丹利 | $19→$11 | 评级下调 | 超重→等重 |
| 07/29/2022 | 150% | 杰富瑞 | →$9 | 开始承保 | →购买 |
| 2022年05月12日 | 344.44% | HC Wainwright公司 | $62→$16 | 维护 | 买 |
| 03/17/2022 | 427.78% | 摩根士丹利 | $20→$19 | 维护 | 超重 |
| 03/15/2022 | 177.78% | B of A证券 | $50→$10 | 评级下调 | 购买→中性 |
| 02/28/2022 | 233.33% | 巴克莱 | $20→$12 | 评级下调 | 超重→等重 |
| 2021年11月17日 | 455.56% | 巴克莱 | $33→$20 | 维护 | 超重 |
| 10/11/2021 | 872.22% | 摩根士丹利 | $60→$35 | 升级 | 等重→超重 |
| 10/08/2021 | 816.67% | 巴克莱 | $80→$33 | 维护 | 超重 |
| 07/27/2021 | 1566.67% | B of A证券 | →$60 | 升级 | 中性→购买 |
| 04/26/2021 | 1622.22% | HC Wainwright公司 | →$62 | 开始承保 | →购买 |
| 03/17/2021 | 1566.67% | 摩根士丹利 | $47→$60 | 维护 | 等重 |
| 12/16/2020 | 1205.56% | 摩根士丹利 | $38→$47 | 维护 | 等重 |
| 2020年11月12日 | 955.56% | 摩根士丹利 | $34→$38 | 维护 | 等重 |
| 10/20/2020 | 1011.11% | B of A证券 | →$40 | 开始承保 | →购买 |
| 10/20/2020 | 927.78% | 高盛 | →$37 | 开始承保 | →中性 |
| 10/20/2020 | - | 摩根士丹利 | 开始承保 | →等重 |
What is the target price for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的目标价格是多少？
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by Morgan Stanley on August 4, 2023. The analyst firm set a price target for $10.00 expecting PRLD to rise to within 12 months (a possible 177.78% upside). 7 analyst firms have reported ratings in the last year.
摩根士丹利于2023年8月4日报道了Prelude Treateutics(纳斯达克：PRLD)的最新目标价。这家分析公司将目标价定为10美元，预计PRLD将在12个月内上涨(可能上涨177.78%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的最新分析师评级是什么？
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by Morgan Stanley, and Prelude Therapeutics reiterated their equal-weight rating.
普瑞德治疗公司(纳斯达克代码：PRLD)的最新分析师评级由摩根士丹利提供，普瑞鲁治疗公司重申其同等权重的评级。
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Prelude Treeutics(PRLD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Prelude Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Prelude治疗公司的最后一次评级是在2023年8月4日提交的，所以你应该预计下一次评级将在2024年8月4日左右的某个时候提供。
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
分析师对Prelude Treeutics(PRLD)的评级正确吗？
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a reiterated with a price target of $10.00 to $10.00. The current price Prelude Therapeutics (PRLD) is trading at is $3.60, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Prelude Treeutics(PRLD)评级被重申，目标价在10.00美元至10.00美元之间。Prelude Treateutics(PRLD)目前的交易价格为3.60美元，超出了分析师的预测范围。